Nasdaq:CBIO
CRESCENT BIOPHARMA, INC.
A cash-rich biopharma developer advancing a pipeline of novel therapies with minimal current revenue but strong financing capabilities.
Key Metrics
Investment Thesis
Bull Case
Investors may view this stock as a high-risk, high-reward opportunity given the company's pristine balance sheet with $213M in cash and minimal debt. The recent capital raise indicates strong market validation of the company's technology platform and potential for future commercial success if clinical trials succeed.
Bear Case
The company is losing over $150M per year with no current product revenue to offset these massive losses, creating a dangerous burn rate that could lead to insolvency without further dilution. The lack of established revenue streams beyond the initial $10.8M makes valuation extremely speculative and dependent on uncertain future clinical outcomes.
About CRESCENT BIOPHARMA, INC.
Crescent Biopharma is a biotechnology company focused on developing innovative therapies, currently operating with minimal revenue but significant cash reserves. The company serves the global pharmaceutical market through its extensive research and development pipeline aimed at addressing unmet medical needs. With substantial capital raised recently, the firm is positioned to advance its clinical-stage assets toward potential commercialization.
Analysis
Management Discussion
Management has achieved a massive cash infusion of $323M which increased total cash holdings from $34.8M to $213.3M, effectively solving near-term solvency concerns despite the widening net loss. However, the substantial increase in operating expenses and R&D spending suggests aggressive clinical trial expansion that has pushed the net income deficit to -$153.9M.
Industry Overview
The biotechnology sector is characterized by high capital intensity, long development cycles, and significant regulatory hurdles before products reach market. Companies in this space often trade at valuations disconnected from current earnings but based entirely on the potential value of their drug pipelines and intellectual property portfolios.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $75.0K | $10.0K | $0 | $10.8M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $75.0K | $10.0K | $0 | $10.8M |
| Operating Expenses | $47.5M | $39.3M | $40.0M | $163.5M |
| Operating Income | $-47.4M | $-39.3M | $-40.0M | $-152.6M |
| R&D | $28.4M | $20.1M | $14.3M | $138.1M |
| G&A | $19.1M | $19.2M | $18.2M | $25.4M |
| Stock-Based Comp | $3.9M | $3.5M | $4.7M | $13.3M |
| Depreciation | $207.1K | $153.3K | $35.2K | $84.0K |
| Other OpEx | $0 | $0 | $7.5M | $0 |
| Non-Operating Income | $0 | $0 | $0 | $690.0K |
| Pre-Tax Income | $-47.4M | $-39.3M | $-40.0M | $-151.9M |
| Income Tax | $-714.5K | $-2.4M | $-2.2M | $2.0M |
| Continuing Ops | $-46.7M | $-36.9M | $-37.9M | $-153.9M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-46.7M | $-36.9M | $-37.9M | $-153.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-46.7M | $-36.9M | $-37.9M | $-153.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $50.7M | $43.8M | $11.1M | $236.7M |
| Cash & Equivalents | $47.9M | $41.8M | $10.7M | $213.2M |
| Accounts Receivable | — | — | — | $18.0M |
| Prepaid Expenses | $2.8M | $2.0M | $371.3K | $5.5M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $1.1M | $1.5M | $0 | $3.6M |
| PP&E (Net) | $242.4K | — | — | $846.0K |
| Operating Leases | $751.2K | $767.8K | — | $1.5M |
| Other LT Assets | $102.3K | $757.9K | — | $1.3M |
| Total Assets | $51.8M | $45.3M | $11.1M | $240.3M |
| Current Liabilities | $8.9M | $6.8M | $5.8M | $36.1M |
| Accounts Payable | $970.2K | $868.1K | $329.3K | — |
| Current Leases | $918.6K | $741.6K | $66.8K | $435.0K |
| Deferred Revenue | — | — | — | $4.2M |
| Other Current Liab | $0 | $0 | $0 | $15.1M |
| Long-Term Liabilities | $0 | $66.8K | $0 | $1.2M |
| LT Operating Leases | — | $66.8K | — | $1.2M |
| Other LT Liab | — | $0 | — | $0 |
| Total Liabilities | $8.9M | $6.9M | $5.8M | $37.3M |
| Shareholders' Equity | $42.9M | $38.4M | $5.3M | $203.0M |
| Paid-In Capital | $462.5M | $494.8M | $499.6M | $370.8M |
| Retained Earnings | $-419.6M | $-456.5M | $-494.4M | $-171.8M |
| Total L&E | $51.8M | $45.3M | $11.1M | $240.3M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-46.7M | $-36.9M | $-37.9M | $-153.9M |
| Non-Cash Adjustments | $781.8K | $4.7M | $8.8M | $50.1M |
| Working Capital Changes | $-550.5K | $-2.7M | $-2.1M | $32.3M |
| Cash from Operations | $-46.5M | $-34.9M | $-31.1M | $-71.5M |
| Capital Expenditures | $84.2K | $21.4K | $10.0K | $919.0K |
| Cash from Investing | $-84.2K | $-21.4K | $20.0K | $-72.9M |
| Cash from Financing | $4.2M | $28.8M | $5.4K | $323.0M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $-42.4M | $-6.1M | $-31.1M | $178.5M |
| Beginning Cash | $90.3M | $47.9M | $41.8M | $34.8M |
| Ending Cash | $47.9M | $41.8M | $10.7M | $213.3M |
Frequently Asked Questions
How does CRESCENT BIOPHARMA, INC. make money?
The company's financial profile indicates a primary focus on Research and Development activities, evidenced by $138.1M in R&D spending against negligible cost of revenue. Revenue is currently generated from early-stage commercialization or licensing agreements totaling $10.8M, while the balance sheet reflects heavy investment in operating intangibles and clinical trial assets.
What are the main risks for CBIO?
The company is burning through cash at a rapid rate of approximately $154M annually with no clear path to profitability yet. Heavy reliance on future successful drug approvals and the ability to secure additional capital raises as current funds deplete. Significant operating expenses of $163.5M driven by R&D and administrative costs threaten liquidity if revenue growth does not accelerate quickly.
What is CBIO's competitive advantage?
Significant cash on hand of over $213M provides a robust runway to fund high-cost clinical trials without immediate dilution pressure. The company has successfully executed a major financing round generating $323M in cash flow from financing activities, demonstrating strong investor confidence and capital raising ability.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.